Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among

Michelle P Aranha1,2, Thomas A Penfound3, Jay A Spencer4

  • 1Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee 37996, United States maranha@utk.edu.

Insights

Developing a Group A Streptococcus (Strep A) vaccine requires understanding M protein cross-reactivity. This study identified key sequence features for broad protection against diverse Strep A types.

Area of Science:

  • Immunology
  • Structural Biology
  • Vaccine Development

Background:

  • Group A Streptococcus (Strep A) surface M protein is crucial for virulence and a vaccine target.
  • The M protein's N-terminal region determines M type and contains epitopes for opsonophagocytic killing.
  • Cross-reactivity among M types suggests potential for a broadly protective multivalent Strep A vaccine.

Purpose of the Study:

  • To construct a recombinant M protein-based vaccine targeting Strep A.
  • To identify cross-protective epitopes for a broadly protective multivalent Strep A vaccine.
  • To develop a predictive algorithm for selecting optimal M peptide vaccine candidates.

Main Methods:

  • Immunological assays
  • Structural biology
  • Cheminformatics
  • Recombinant vaccine construction
  • Antisera cross-reactivity testing
  • Sequence identity analysis
  • Polar helical-wheel heptad site analysis

Main Results:

  • A recombinant vaccine with six Strep A M peptides was created.
  • Rabbit antisera cross-reacted with 10 out of 15 tested nonvaccine M types.
  • High sequence identity alone did not guarantee cross-reactivity; polar heptad site identity was a key predictor.
  • A scoring algorithm based on polar heptad site identity was developed.

Conclusions:

  • Sequence identity at specific polar helical-wheel heptad sites accurately predicts M peptide cross-reactivity.
  • The developed algorithm can guide the selection of minimal M peptide vaccine candidates for broad Strep A protection.
  • This approach facilitates the development of effective multivalent vaccines against Group A Streptococcus.